卫宁健康科技集团股份有限公司 2022 年第三季度报告 1 证券代码：300253 证券简称：卫宁健康 公告编号：2022-082 卫宁健康科技集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 卫宁健康科技集团股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | |-------|------------------------------------------------------|------------------|--------------- ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders for the same period was 200 million RMB, up 10% compared to the previous year[18]. - The company's operating revenue for the reporting period was ¥1,095,923,090.27, representing a year-on-year increase of 6.98%[26]. - Net profit attributable to shareholders decreased by 40.09% to ¥66,897,245.68 compared to the same period last year[26]. - The net profit after deducting non-recurring gains and losses was ¥68,926,834.22, down 21.25% year-on-year[26]. - Future guidance indicates a projected revenue growth of 25% for the full year 2022[18]. - The company reported a total revenue of 1.5 billion RMB for the first half of 2022, representing a year-over-year increase of 20%[200]. - The company has set a revenue guidance of 3.2 billion RMB for the full year 2022, reflecting an expected growth of 15% compared to 2021[200]. User Growth - User data showed an increase in active users to 5 million, reflecting a growth rate of 20% year-on-year[18]. - User data showed an increase in active users to 10 million, up from 8 million in the previous year, indicating a growth rate of 25%[200]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[18]. - Market expansion efforts have led to a 40% increase in sales in the Southeast Asia region, with plans to enter two additional markets by the end of 2022[200]. Product Development - New product launches are expected to contribute an additional 300 million RMB in revenue for the second half of 2022[18]. - New product launches contributed to 30% of total revenue, highlighting the importance of innovation in driving sales[200]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing service delivery and user experience[200]. Research and Development - The company has invested 100 million RMB in R&D for new technologies, aiming to enhance its product offerings and improve user experience[18]. - Company研发投入为2.77亿元，占营业收入的25.27%[46]. - Research and development expenses increased by 15.50% to ¥277,378,922.24 from ¥240,155,515.11 in the previous year[66]. Strategic Partnerships and Acquisitions - Strategic partnerships are being pursued to enhance service capabilities and expand the customer base[18]. - The company completed a strategic acquisition of a local tech firm for 500 million RMB to bolster its capabilities in AI[200]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year[6]. - The company reported a significant increase in financial expenses by 104.20%, amounting to ¥19,417,026.46, primarily due to interest accrued on convertible bonds[66]. - The company reported a net cash outflow from financing activities of -¥129,989,317.25, a decrease of 123.79% compared to the previous year due to the absence of funds raised from issuing convertible bonds[66]. Risk Management - The company is actively managing risks related to technology development and market competition, with a focus on maintaining operational stability[5]. - The company faces risks related to technology and product development, emphasizing the need for continuous innovation to maintain market advantages[106]. - Increased competition in the healthcare information industry necessitates enhanced management measures and R&D investment to sustain core competitive advantages[107]. - The ongoing COVID-19 pandemic poses risks to business operations, requiring proactive monitoring and response strategies[113]. Shareholder Information - The company reported a total of 73,561 shareholders at the end of the reporting period, with the largest shareholder, Zhou Wei, holding 8.22% of the shares[180]. - The company has repurchased 14,256,400 shares, accounting for 0.66% of the total share capital, with a total transaction amount of 120,623,771.16 yuan[164]. - The company’s total share capital increased by 1,298,781 shares due to stock option exercises during the reporting period[172]. Compliance and Governance - The company has maintained compliance with relevant laws and regulations, ensuring transparency and timely information disclosure to investors[134]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[142]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[138].

卫宁健康科技集团股份有限公司 2022 年第一季度报告全文 1 证券代码：300253 证券简称：卫宁健康 公告编号：2022-035 卫宁健康科技集团股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | 本报告期 | ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year growth of 15%[21] - The net profit attributable to shareholders was 200 million RMB, an increase of 10% compared to the previous year[21] - The company's operating revenue for 2021 was ¥2,750,202,059.34, representing a 21.34% increase compared to ¥2,266,579,783.89 in 2020[28] - The net profit attributable to shareholders for 2021 was ¥378,174,115.45, a decrease of 22.99% from ¥491,097,996.59 in 2020[28] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥211,903,243.56, down 43.20% from ¥373,041,370.27 in 2020[28] - The total revenue for 2021 reached approximately ¥2.75 billion, representing a year-over-year increase of 21.34% from ¥2.27 billion in 2020[74] - The revenue from the healthcare information technology sector was approximately ¥2.31 billion, accounting for 84.04% of total revenue, with a growth of 9.33% compared to the previous year[74] - The internet healthcare sector saw significant growth, with revenue of approximately ¥438.6 million, a 191.61% increase from ¥150.4 million in 2020, representing 15.93% of total revenue[74] Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2023[21] - The company aims for a revenue growth target of 20% for the upcoming fiscal year[21] - Strategic acquisitions are planned to enhance service offerings, with a budget of 500 million RMB allocated for potential targets[21] - The company plans to expand its market presence in the internet healthcare sector, which has shown rapid growth and high demand[81] - The company intends to strengthen market coverage and increase market share by leveraging the demand for digital healthcare across various provinces[147] Research and Development - The company has invested 100 million RMB in R&D for new technologies, focusing on AI and big data applications in healthcare[21] - The company invested approximately ¥54.9 million in R&D, which accounted for 19.96% of total revenue, and applied for 90 new patents during the reporting period[71] - The company aims to enhance product competitiveness through various ongoing R&D projects, including smart hospital solutions and medical knowledge databases[97] - The company is focusing on deepening the development of industrialized products and accelerating upgrades to maintain technological advantages[149] - The company aims to increase R&D investment and closely monitor industry trends to strengthen its core competitive advantages in user numbers and technology[150] Operational Efficiency and Financial Management - The company acknowledges risks related to technology development and market competition, emphasizing the need for strategic management[7] - The company’s revenue is seasonally distributed, with the first half of the year typically accounting for only 20%-30% of annual revenue, while the fourth quarter can reach over 50%[78] - The company is focusing on enhancing its supply chain management capabilities as part of its strategic initiatives[132] - The company aims to improve operational efficiency through the implementation of digital solutions in its service offerings[132] Governance and Shareholder Engagement - The company held 5 shareholder meetings during the reporting period, ensuring all shareholders had sufficient speaking rights and access to information on major matters[162] - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[163] - The company has established a comprehensive governance framework that aligns with the requirements of the Company Law and relevant regulations[161] - The company strictly adheres to information disclosure regulations, ensuring timely and accurate information is available to all shareholders[166] - The company has not engaged in any direct or indirect interference in decision-making by the controlling shareholder during the reporting period[167] Risks and Challenges - The company faces risks related to technology and product development due to rapid updates in software products and technology, which may lead to loss of market advantage if not managed properly[149] - The healthcare information industry is experiencing intensified competition, with an increasing number of market participants, necessitating the company to enhance its competitiveness and core advantages[150] - The company is at risk of goodwill impairment if acquired assets do not perform as expected, which could negatively impact financial results[155] - The software industry is characterized by high personnel turnover, which poses a risk to the company's innovation capabilities if key talent is lost[154] Investment and Financial Performance - The total investment amount for the reporting period was ¥468,916,000, representing a 764.40% increase compared to ¥61,344,300 in the previous year[122] - The company reported a significant increase in investment income, with a loss of approximately ¥39.04 million, accounting for -10.46% of total profit[116] - The fair value changes in non-current financial assets generated a profit of approximately ¥155.55 million, accounting for 41.68% of total profit[116] - The company reported a net loss of approximately ¥21.49 billion for 2021, a significant increase from a net loss of ¥13.04 billion in 2020, reflecting a growth rate of -64.84%[70]

卫宁健康科技集团股份有限公司 2021 年第三季度报告 1 证券代码：300253 证券简称：卫宁健康 公告编号：2021-121 卫宁健康科技集团股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|------------------------|------------------|---------- ...

卫宁健康科技集团股份有限公司 2021 年半年度报告全文 卫宁健康科技集团股份有限公司 2021 年半年度报告 2021 年 08 月 1 卫宁健康科技集团股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人周炜、主管会计工作负责人王利及会计机构负责人(会计主管人 员)陈旭纹声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | --- | |----------------------------------------------------------------------|-------------------| | | | | 本报告中所涉及的未来计划、发展战略等前瞻性描述，并不代表公司的盈 | | | 利预测，也不构成公司对任何投资者及相关人士的实质承诺，投资者及相关人 | | | 士均应对此保持足够认识，并且应当理解计划、预测与承诺之间的差异。请投 | ...

Financial Performance - The company's revenue for Q1 2021 was ¥344,702,672.33, representing a 24.01% increase compared to ¥277,973,283.64 in the same period last year[8] - Net profit attributable to shareholders was ¥14,325,009.37, up 21.93% from ¥11,748,072.92 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥775,449.63, a significant decrease of 92.80% compared to ¥10,774,757.23 in the previous year[8] - Basic earnings per share increased to ¥0.0067, a rise of 19.64% from ¥0.0056 year-on-year[8] - Operating revenue for the reporting period reached 344.70 million yuan, a year-on-year increase of 24.01%[30] - Net profit attributable to shareholders was 14.32 million yuan, up 21.93% year-on-year; however, net profit after deducting non-recurring gains and losses dropped 92.80% to 0.78 million yuan[30] Cash Flow and Liquidity - The net cash flow from operating activities was -¥198,421,096.06, an improvement of 7.32% from -¥214,082,270.13 in the same period last year[8] - Cash inflow from financing activities was CNY 969 million, significantly higher than CNY 74 million in the previous year[106] - Net cash flow from financing activities was CNY 891 million, compared to a negative CNY 28.83 million in the previous year[106] - The ending cash and cash equivalents balance was CNY 1.22 billion, up from CNY 127 million year-over-year[110] - The company reported a net increase in cash and cash equivalents of CNY 724 million, contrasting with a decrease of CNY 205 million in the previous year[110] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,802,457,168.68, reflecting a 12.30% increase from ¥6,057,147,858.20 at the end of the previous year[8] - The company's total liabilities increased to ¥1,914,113,584.76 from ¥1,342,908,093.38, representing a rise of 42.5%[71] - The company's total equity increased to ¥4,888,343,583.92 from ¥4,714,239,764.82, representing a growth of 3.7%[71] - The company's accounts receivable stood at ¥592,145,527.34, slightly up from ¥584,710,116.09, indicating a growth of 1.5%[65] - The company's inventory increased to ¥133,105,736.83 from ¥128,263,118.58, marking a growth of 3.0%[65] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 83,852[12] - The largest shareholder, Zhou Wei, holds 10.24% of the shares, amounting to 219,304,241 shares[13] Investment and R&D - Research and development expenses increased to CNY 62,897,860.31, compared to CNY 49,011,570.48 in the previous period[86] - The company emphasizes the importance of maintaining a competitive edge in technology and user engagement through increased R&D investment[39] - The company is committed to improving its corporate culture to attract and retain talent, utilizing various compensation methods including performance rewards and stock incentives[40] Business Operations - The medical health information business accounted for 84.68% of total revenue, growing 7.28% year-on-year, while internet health business revenue surged 928.63% to represent 15.21% of total revenue[30] - The company added over 100 medical institutions to its unified payment platform, with transaction amounts exceeding 11 billion yuan, a year-on-year growth of approximately 100%[33] - As of March 31, 2021, the online service platform of Nari Health completed over 5 million transactions, with over 30 million registered patients[33] Risk Management - The company faces a talent retention risk due to high turnover in the software industry, which could impact its innovation and market competitiveness[40] - The company is conducting annual impairment tests on goodwill to mitigate risks associated with potential declines in acquired assets' performance[44] - The company aims to strengthen its internal control management system to minimize the impact of goodwill on future performance[44] Corporate Governance - The company has completed the election of the fifth board of directors and the fifth supervisory board, with announcements made regarding the appointments of senior management and securities affairs representatives[52] - The company has implemented a restricted stock incentive plan, with the list of incentive objects being reviewed and publicized[52] Fundraising Activities - The company has raised approximately 970.27 million yuan through the issuance of convertible bonds, with 9.70265 million bonds issued[45] - The total amount of raised funds is 96,120.96 million, with no changes in usage or percentage of changes[53] Future Plans - The company plans to enhance its competitive edge by aligning product development with national policies and industry demands, addressing risks related to technology and market competition[38] - The company plans to enhance its management capabilities and establish a standardized governance structure to address the management risks associated with rapid expansion and acquisitions[39]

卫宁健康科技集团股份有限公司 2020 年年度报告全文 卫宁健康科技集团股份有限公司 2020 年年度报告 2021 年 04 月 1 卫宁健康科技集团股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人周炜、主管会计工作负责人王利及会计机构负责人(会计主管人 员)陈旭纹声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |-----------------------------------------------------------------------------------------| | | | 本报告中所涉及的未来计划、发展战略等前瞻性描述，并不代表公司的盈 | | 利预测，也不构成公司对任何投资者及相关人士的实质承诺，投资者及相关人 | | 士均应对此保持足够认识，并且应当理解计划、预测与承诺之间的差异。请投 | | 资者认真阅读本年度报告全文，并注 ...

Financial Performance - Operating revenue for the reporting period was ¥578,063,780.58, representing a year-on-year growth of 9.42%[8] - Net profit attributable to shareholders was ¥128,713,131.40, an increase of 16.23% compared to the same period last year[8] - Basic earnings per share for the reporting period was ¥0.0609, up 15.34% from the previous year[8] - The weighted average return on net assets was 3.26%, a slight increase of 0.06% compared to the previous year[8] - The net profit attributable to shareholders decreased by 25.49% year-to-date compared to the same period last year[8] - Revenue for the first three quarters of 2020 reached 1,371.37 million yuan, a year-on-year increase of 14.49%[25] - Net profit attributable to shareholders for the first three quarters of 2020 was 203.37 million yuan, a year-on-year decrease of 25.49%[25] - The innovative business segment reported a total revenue of 187.79 million RMB for the first three quarters of 2020, representing a 13.87% increase year-on-year[33] - The revenue from Nali Health increased by 52.40% year-on-year, reaching 254.14 million RMB[33] - Total operating revenue for the current period reached ¥1,371,372,671.06, an increase of 14.5% compared to ¥1,197,832,903.20 in the previous period[88] - Net profit for the current period was ¥197,309,532.20, a decrease of 21.8% from ¥252,517,836.58 in the previous period[91] Cash Flow and Assets - The net cash flow from operating activities was ¥31,827,465.55, a significant increase of 229.48% year-on-year[8] - Bank deposits decreased by 40.86% compared to the beginning of the year, mainly due to payments made during the reporting period[25] - Accounts receivable increased by 118.91% compared to the beginning of the year, primarily due to an increase in received bills[25] - The company reported a total current assets of RMB 2,726,286,589.39 as of September 30, 2020, compared to RMB 2,605,953,713.12 at the end of 2019, reflecting an increase of approximately 4.63%[54]. - Cash and cash equivalents at the end of the period totaled 415,745,039.75 CNY, up from 265,886,196.40 CNY in the previous year, representing a significant increase of approximately 56.2%[107] - The company reported a net cash flow from investing activities of -122,717,664.30 CNY, which is an improvement from -209,885,302.70 CNY in the previous year[107] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 90,634[12] - The largest shareholder, Zhou Wei, holds 10.28% of the shares, totaling 219,304,241 shares[12] - The company has a total of 407,225,669 restricted shares, with no new restricted shares added during the reporting period[21] - The company’s major shareholders include Zhou Wei and Wang Ying, who are the actual controllers, holding a combined total of 181,785,180 shares[18] - The company did not engage in any repurchase transactions during the reporting period[17] Operational Developments - The number of registered doctors on the Nali Health platform exceeded 280,000, a year-on-year increase of 270%[29] - The number of registered patients on the Nali Health platform exceeded 15 million, a year-on-year increase of 400%[29] - The total transaction amount for unified payment business reached 53 billion yuan, with a year-on-year growth of over 60%[29] - The new generation medical technology product WiNEX has been launched in multiple hospitals, winning the "Dingxin Cup" award for outstanding solutions[28] - The company successfully won bids for provincial medical insurance projects, enhancing its capabilities for future business development[30] Future Outlook and Strategy - The company plans to issue convertible bonds totaling up to 989 million RMB to fund new generation smart medical product development and cloud service projects[36] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2021[138] - Strategic partnerships are being explored to enhance service offerings, with potential collaborations expected to be finalized by Q1 2021[138] - The company is considering acquisitions to bolster its technology capabilities, with a budget of 15 million earmarked for potential targets[138] Research and Development - Research and development expenses increased to 56,875,342.28 from 50,726,428.63, marking a rise of about 12.47%[76] - New product development initiatives are underway, with an investment of 5 million allocated for R&D in innovative healthcare solutions[138]

卫宁健康科技集团股份有限公司 2020 年半年度报告全文 卫宁健康科技集团股份有限公司 2020 年半年度报告 2020 年 08 月 1 卫宁健康科技集团股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连 带的法律责任。 公司负责人周炜、主管会计工作负责人王利及会计机构负责人(会计主管人 员)陈旭纹声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |--------------------------------------------------------------------------| | | | 本报告中所涉及的未来计划、发展战略等前瞻性描述，并不代表公司的盈 | | 利预测，也不构成公司对任何投资者及相关人士的实质承诺，投资者及相关人 | | 士均应对此保持足够认识，并且应当理解计划、预测与承诺之间的差异。请投资 | | 者认真阅读本报告全文，并注意公司可能存在的技术与产 ...